Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tDCS vs Risperidone in Children with ASD
NCT05491720Phase 1Completed
- Sponsor
- National Brain Mapping Laboratory
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial (3 arms), sponsored by National Brain Mapping Laboratory. Primary endpoints: Gilliam Autism Rating Scale at 3 months, Verbal Fluency Task at 3 months and 1 more. Started Aug 2020; status: completed.
Beyond the preview
Go deeper on NCT05491720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491720.